louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06096051: Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage
Official title: Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Intracranial Hemorrhage
Lead sponsor: Methodist Health System
Sponsor class: OTHER
First posted: 2023-10-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients 18 years of age

* ICH (traumatic and spontaneous)
* Administration of at least one dose of 4F-PCC
* Admitted to the MHS between July 1, 2018 and May 30, 2023
* Rivaroxaban or apixaban use prior to admission

Brief summary: Intracranial hemorrhage (ICH) can occur due to traumatic and spontaneous events.1 The incidence of non-traumatic, spontaneous ICH is approximately 40,000 to 67,000 cases per year while the incidence of traumatic brain injury (TBI) is nearly 1.7 million annually

Detailed description: The authors found that AC use preinjury was associated with ICH progression, immediate neurosurgery intervention, and death after initial scan. AC use has also been associated with worse functional outcomes, and patients are less likely to be discharged home compared to those without AC use prior to injury.6 With increasing prevalence of AC, hospitals are seeing admissions for ICH, making knowledge of optimal AC reversal essential.

Eligibility criteria: Inclusion Criteria:

* • ≥18 years of age

  * ICH (traumatic and spontaneous)
  * Administration of at least one dose of 4F-PCC
  * Admitted to the MHS between July 1, 2018 and May 30, 2023
  * Rivaroxaban or apixaban use prior to admission

Exclusion Criteria:

* • Warfarin or dabigatran use prior to admission

  * Prisoners
  * Pregnancy
  * \<18 years of age

Primary outcomes:
measure: Determine safety and effectiveness of 4F-PCC
timeFrame: 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Methodist Dallas Medical Center
state: Texas
Study officials:
affiliation: Methodist Midlothian Medical Center
name: Tamara Reiter, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tenny S, Das JM, Thorell W. Intracranial Hemorrhage. 2024 Feb 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK470242/
Clinical trial NCT04448951: Immune Homeostasis in Sepsis and Septic Shock
Official title: Immune Homeostasis in Patients With Sepsis and Septic Shock: a Single Center Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sepsis
Immunologic Paralysis
Immunologic Suppression
Immune Deficiency
Keywords: sepsis
septic shock
immune response
immunoparalysis
transcriptomics
flow-cytometry
immunomodulation
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
First posted: 2020-06-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: sepsis/septic shock according SEPSIS-3 definition

Brief summary: Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.


Eligibility criteria: Inclusion Criteria:

* sepsis/septic shock (SEPSIS-3)
* age ≥18
* informed consent
* inclusion within first 24hrs after development/diagnosis of septic shock

Exclusion Criteria:

* disagreement of the patient or legal representative with the entry into the study
* patients with primary or secondary immunodeficiency
* presence of active haematological malignancy or an active non-haematological malignancy

Primary outcomes:
measure: Immune response description - flow cytometry
timeFrame: 2024 - 2026
measure: Immune response description - transcriptomics
timeFrame: 2024 - 2026
measure: Immune response description - ELISA
timeFrame: 2024 - 2026
Secondary outcomes:
measure: Diagnostic "immune status" panel
timeFrame: 2026 - 2028
Other outcomes:
Locations:
city: Pilsen
country: Czechia
facility: Medical ICU, 1st Dept. of Internal Medicine, Teaching Hospital in Pilsen
state: Česká Republika
Study officials:
affiliation: Carles University Teaching Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic
name: Thomas Karvunidis, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07012551: Endovascular Modalites for Contralateral Common Iliac Artery in Patients With Symptomatic Unilateral Common Iliac Artery Occlusive Disease
Official title: Endovascular Modalites for Contralateral Common Iliac Artery in Patients With Symptomatic Unilateral Common Iliac Artery Occlusive Disease
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Iliac Artery Disease
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-06-10
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients attending the Vascular Surgery Clinics in Assiut University Hospitals complaining of unilateral CIA ostial occlusive disease, Rutherford category 3, 4and 5 will be recruited to participate in the study.

Brief summary: To evaluate the safety, efficacy, and outcomes of endovascular strategies for protection of the contralateral CIA in patients with symptomatic unilateral CIA occlusive disease


Eligibility criteria: Inclusion Criteria:

* Symptomatic patients (Rutherford category 3- 5) due to Unilateral common iliac artery occlusive disease.

with or without combined iliac or femoropopliteal or infrapopliteal lesions.

Asymptomatic Contralateral limb.

Patent at least one run-off vessel

Exclusion Criteria:

* Distal aorta lesion

contralateral CIA occlusion

Previous endovascular or surgical procedures for the same lesion

Hypersensitivity to contrast material

Presence of aortic or iliac aneurysms

Patients with unsalvageable limb

Non atherosclerotic lesions

Primary outcomes:
measure: Primary patency of both common iliac arteries
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010 Mar 2;55(9):898-903. doi: 10.1016/j.jacc.2009.09.055.
Clinical trial NCT01117051: Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
Official title: A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride in Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Non-cancer Pain
Opioid Induced Constipation
Keywords: Opioid induced constipation/prucalopride chronic non-cancer pain
Subjects with chronic non-cancer pain suffering from OIC
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2010-05-05
Enrollment: 174
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will evaluate the efficacy, safety and tolerability of prucalopride over 12 weeks of treatment in subjects aged 18 years and older with chronic non-cancer pain, suffering from opioid induced constipation.


Eligibility criteria: Inclusion criteria to be assessed at screening:

1. Male or non-pregnant, non-breast-feeding female outpatient ≥18 years.
2. Has chronic pain of any aetiology (except cancer pain) requiring daily maintenance treatment with opioids;has been on stable daily opioid dose during at least the previous 2 weeks; and is expected to remain on stable daily dose of opioids for at least 15 weeks after Visit 1.
3. Subject is suffering from OIC (i.e. secondary to chronic opioid use).
4. Subject agrees to stop his/her laxative treatment and is willing to use rescue medication.

Main exclusion criteria to be assessed at screening:

1. Constipation is thought to be drug-induced (except for opioids)
2. Disallowed medication is being used
3. Subject was on chronic therapy for chronic constipation prior to start of opioid therapy
4. Subject is suffering from secondary causes of chronic constipation.

Primary outcomes:
measure: Percent of Subjects With an Average Frequency of >=3 Spontaneous Bowel Movements Per Week
timeFrame: 12 weeks
Secondary outcomes:
measure: Plasma Concentration of Prucalopride at Week 2
timeFrame: Week 2
measure: Plasma Concentration of Prucalopride at Week 8
timeFrame: Week 8
Other outcomes:
Locations:
city: Leuven
country: Belgium
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT03746951: Comparative Evaluation of Lumbar Plexus and Suprainguinal Fascia Iliaca Compartment Blocks
Official title: Comparative Evaluation of Lumbar Plexus and Suprainguinal Fascia Iliaca Compartment Blocks for Pain Management After Orthopedic Surgical Procedures Involving Hip and Femur in Pediatrics.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Orthopedic Disorder
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2018-11-20
Enrollment: 15
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators aim to compare the use of a suprainguinal fascia iliaca compartment block vs lumbar plexus block as an adjunct to general anesthesia in pediatric patients undergoing orthopedic procedures involving the hip or upper femur. This study will help determine the efficacy of the two techniques and their advantages when compared to each other including time to perform the block, opioid consumption reduction, effects on postoperative pain, and the length of stay.


Eligibility criteria: Inclusion Criteria:

* ASA grade I-III
* Undergoing elective orthopedic surgical procedures involving the hip and upper thigh

Exclusion Criteria:

* Local anesthetic allergy
* Skin or localized infection at the site of catheter insertion
* Patient or parent refusal

Primary outcomes:
measure: Total Time to Perform the Regional Anesthesia Technique
timeFrame: Baseline
Secondary outcomes:
measure: Opioid Consumption in the PACU
timeFrame: Immediately to 1 hour post-op
measure: Post-op Pain Scores
timeFrame: 48 hours post-op
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT05884151: Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
Official title: Comparative Efficacy of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Melasma
Lead sponsor: Combined Military Hospital Abbottabad
Sponsor class: OTHER
First posted: 2023-06-01
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: ABSTRACT Objective: To study the efficacy while comparing Intralesional tranexamic acid Vs Platelets rich plasma (PRP) in treatment of Melasma.

Study design: Randomized-controlled trial (RCT). Study setting and duration: Dept of dermatology, CMH-Abbottabad, Nov-2022 /April-2023.

Methodology: The sample size of 60 patients 20 to 40 years were calculated by using Openepi App. The informed consent was taken. The patients were randomly allocated to two groups: Group A (30 patients injected with Intradermal Tranexamic acid (4mg/ml) and Group B (30 patients treated with PRP (1ml) intra-dermally, every fourth week for up to 12 weeks between both groups). The mMASI scale was used to evaluate all patients. The final evaluation was performed on the 24th week of follow-up. For analysis Statistical Package for the social sciences version-27 was used. To determine statistical significance a paired t-samples test with a p-value of \< 0.05 was applied.


Eligibility criteria: Inclusion Criteria:

* 20_40 years of age
* suffering from melasma

Exclusion Criteria:

* pregnancy
* breastfeeding mothers
* allergic to tranexamic acid
* bleeding disorders
* warts or facial eczema

Primary outcomes:
measure: Melasma severity index
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Abbottabad
country: Pakistan
facility: Dr sana aslam
state: Khyber Pakhtun Khwaa
city: Abbottabad
country: Pakistan
facility: Sana aslam
state: Khyber Pakhtun Khwa
city: Abbottābād
country: Pakistan
facility: Sana aslam
state: Khyber Pakhtun Khwa
Study officials:
References:
Clinical trial NCT05787951: Frequency and Risk Factors of Acute Myeloid Leukemia
Official title: Frequency and Risk Factors of Acute Myeloid Leukemia at Clinical Haemtology Unit of Assiut University Hospital
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Myeloid Leukemia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-03-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult Patients(above 18 years) diagnosed as acute myeloid leukemia according to WHO diagnostic criteria

Brief summary: 1. to assess the frequency of acute myeloid leukemia at clinical Haematology unit of Assiute university hospital
2. to study correlations of known risk factors and if there are new risk factors participate in increasing frequency of acute myeloid leukemia

Detailed description: Acute myeloid leukaemia (AML) is a rare heterogeneous disease comprising a group of hematopoietic neoplasms originating from the excessive clonal proliferation of myeloid pre- cursor cells \[1\]. Diagnosis of AML is based on morphological diagnosis with proliferation of blast cells ≥ 20% of bone marrow cells, flow cytometric analysis and cytogenetic abnormalities, including the t(8;21)(q22;q22), t(15;17) (q22;q12) and inv (16)(p13.1;q22) which are associated with longer remission and survival, while alterations of chromosomes 5, 7, complex karyotype and 11q23 are associated with poor response to therapy and shorter overall survival \[2\] The etiological agent and pathogenesis of AML are not entirely clear, only few AML cases can be accurately classified through traditional cellular morphological classification \[3\]It is the most common acute leukaemia in adults. It accounts for 1.3% of new cancer patients in the United States, in 2018\[ 4\] Some factors are well documented to increase the risk of some types of leukemia such as benzene exposure and ionizing radiation \[5\] increased frequency of acute myeloid leukemia has been noticed at Haematology unit so the aim of the study to assess the the frequency of acute myeloid leukemia and to evaluate the risk factors for it .

Eligibility criteria: Inclusion Criteria:

* Adult Patients(above 18 years) diagnosed as acute myeloid leukemia according to WHO diagnostic criteria

Exclusion Criteria:

* Patients with other types of leukemia

Primary outcomes:
measure: Frequency of acute myeloid leukemia at clinical Haemtology unit of Assiute university hospital
timeFrame: Two years
Secondary outcomes:
measure: Risk factors of acute myeloid leukemia at clinical Haemtology unit of Assiute university hospital
timeFrame: Two years
Other outcomes:
Locations:
Study officials:
References:
citation: Hwang SM. Classification of acute myeloid leukemia. Blood Res. 2020 Jul 31;55(S1):S1-S4. doi: 10.5045/br.2020.S001.
Clinical trial NCT05657951: Repeatability and Reproducibility of Lens Zonule Length Measurement Using ArcScan Insight 100
Official title: Repeatability and Reproducibility of Lens Zonule Length Measurement Using ArcScan Insight 100 Very High-frequency Digital Ultrasound
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Zonule of Zinn Abnormality
Zonular Cataract
Lead sponsor: Wenzhou Medical University
Sponsor class: OTHER
First posted: 2022-12-20
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy subjects with no ocular disease except ametropia

Brief summary: The purpose of this study is to evaluate the intra-examiner repeatability and inter-examiner reproducibility in lens zonule length measurements using very high-frequency (VHF) digital ultrasound (ArcScan Insight 100).


Eligibility criteria: Inclusion Criteria:

* Subjects with no ocular disease except ametropia
* Subjects will be able to understand and willing to sign an informed consent

Exclusion Criteria:

* Previous ocular surgery
* Subjects not being able to tolerate or not willing to use pilocarpine eye drops
* Subjects has active ocular infection or inflammation
* Subjects not being able to look steadily
* Subjects not being able to open eyes wide in sterile saline even after topical anesthesia

Primary outcomes:
measure: Repeatability of ArcScan Insight 100 zonule scans in normal eyes (standard deviation and coefficient of variation)
timeFrame: 1 day
measure: Reproducibility of ArcScan Insight 100 zonule scans in normal eyes
timeFrame: 1 day
Secondary outcomes:
measure: Repeatability of zonule length measurement with the built-in software (the intraclass correlation)
timeFrame: 1 month
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Eye Hospital of WMU
state: Zhejiang
Study officials:
References:
citation: Li X, Chang P, Li Z, Qian S, Zhu Z, Wang Q, Yun-E Z. Agreement between anterior segment parameters obtained by a new ultrasound biomicroscopy and a swept-source fourier-domain anterior segment optical coherence tomography. Expert Rev Med Devices. 2020 Dec;17(12):1333-1340. doi: 10.1080/17434440.2020.1848541. Epub 2020 Dec 1.
Clinical trial NCT04359251: Different PEEP Settings of COVID-19 Induced ARDS
Official title: Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Mechanical Ventilation Pressure High
Acute Respiratory Distress Syndrome
Keywords: ARDS
COVID-19
mechanical ventilation
PEEP
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This was a multi-center prospective study. All consecutive severe cases of COVID-19 whose PO2/FiO2\<300mmHg with invasive ventilation admitted to 5 fixed-point receive COVID-19 patients hospitals in Wuhan from 5 March to 15 March 2020 were included. Epidemiological, clinical data, lung mechanics, artery blood gas test and hemodynamics at three methods to titrate PEEP, optimizing oxygenation, optimizing compliance, ARDSnet. The study was approved by the Ethics Committee of Zhongda Hsopital, Southeast University.

Detailed description: After PEEP titration, PEEP settings could be set by optimizing oxygenation, optimizing compliance, ARDSnet.

Eligibility criteria: Inclusion Criteria:

* COVID-19 patients with mechanical ventilation
* PO2/FIO2\<300mmHg
* ages\>18 years

Exclusion Criteria:

* pneumothorax
* pregnant
* hemodynamics is unstable

Primary outcomes:
measure: Respiratory system compliance improvement
timeFrame: 20 minutes
Secondary outcomes:
measure: Gas echanges improvement
timeFrame: 20 minutes
Other outcomes:
measure: hemodynamics improvement
timeFrame: 20 minutes
Locations:
city: Nanjing
country: China
facility: Zhongda Hospital, Southeast University
state: Jiangsu
Study officials:
affiliation: Zhongda hospital, Southeast University, Jiangsu, China
name: Chun C Pan
role: STUDY_DIRECTOR
References:
citation: Pan C, Lu C, She X, Ren H, Wei H, Xu L, Huang Y, Xia J, Yu Y, Chen L, Du B, Qiu H. Evaluation of Positive End-Expiratory Pressure Strategies in Patients With Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome. Front Med (Lausanne). 2021 Jul 20;8:637747. doi: 10.3389/fmed.2021.637747. eCollection 2021.
Clinical trial NCT00587951: The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates
Official title: The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Keywords: Clinical decision-making
Ictal SPECT
Epilepsy surgery
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2008-01-08
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients evaluated at Mayo Clinic and being considered for epilepsy surgery.

Brief summary: The aim of this study is to determine the role of SISCOM (see below) in aiding clinicians to manage epilepsy surgery candidates. SISCOM is already a routine component of pre-surgical epilepsy evaluation at Mayo Clinic. In particular, we are interested in assessing whether use of SISCOM can minimize the need for prolonged (\>24 hours) invasive monitoring with electrodes placed on the surface of the brain prior to surgical resection.

Note: this study has recruited the required number of patients and is closed to further enrolment.

Detailed description: Successful epilepsy surgery depends on accurate identification of the area of brain from which seizures originate (the epileptogenic zone). There are many non-invasive tests (including EEG and MRI) to indicate this area. Some patients require implantation of intracranial electrodes in order to determine the epileptogenic zone. A test known as SISCOM (subtraction ictal-interictal SPECT co-registered with MRI) has been validated as a non-invasive means of indicating the epileptogenic zone. However, this test is not widely available in the US, and it is not known how often the additional information provided by SISCOM makes a difference to clinical decision-making.

In order to determine the contribution of SISCOM towards clinical decision-making in epilepsy surgery candidates, we will ask epileptologists at Mayo Clinic to consider case presentations given all clinical information except for SISCOM results, and then to reconsider those same cases in conjunction with SISCOM data. This will indicate the degree to which SISCOM influences decision making.

50 patients at Mayo Clinic (38 adults, 12 children) will be enrolled.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of localization-related epilepsy
* Evaluated by clinical epileptologist at Mayo Clinic
* SISCOM ordered by treating physician
* Case presented at weekly Epilepsy Surgery Conference
* Patient consent

Primary outcomes:
measure: Category of management recommendation (proceed straight to surgical resection, intracranial electrode implantation, more imaging studies OR recommend medical rather than surgical management)
timeFrame: Instantaneous
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Meng Tan, MD
role: PRINCIPAL_INVESTIGATOR
References: